Category: Breaking News

  • Cowboys Cruise Past Cardinals 34-13 as Joe Milton Shines in Preseason Week 2

    Cowboys Cruise Past Cardinals 34-13 as Joe Milton Shines in Preseason Week 2

    TL;DR: The Dallas Cowboys rolled past the Arizona Cardinals 34-13 on Saturday night, improving to 2-0 in the NFL preseason. Quarterback Joe Milton III stole the show, including a 53-yard touchdown bomb, while Phil Mafah added a 15-yard rushing score.

    By Patrick Lancier

    Preseason or not, Cowboys fans got plenty to cheer about. Dallas jumped on Arizona early with a 14-0 first quarter and never looked back, cruising to a 34-13 victory that had “Joe Milton” trending across the United States overnight.

    How did the game unfold?

    Dallas dominated the first half, scoring 14 points in the first quarter and 10 more in the second. Arizona managed only two field-goal-range drives converted into 6 second-quarter points and a third-quarter touchdown. The Cowboys closed it out 34-13, with the scoring spread across all four quarters (14-10-3-7).

    Why is everyone talking about Joe Milton?

    The Cowboys quarterback put together his most convincing outing yet, highlighted by a 53-yard deep-ball touchdown that showcased his famous arm strength. Local media called it the night Milton “put it all together,” leading scoring drive after scoring drive against Arizona’s backups.

    Who else stood out for Dallas?

    Running back Phil Mafah broke a tackle on his way to a 15-yard touchdown run, and the defense turned in another solid performance, holding the Cardinals to 13 points a week after a strong preseason opener.

    What does it mean for the regular season?

    Preseason results should always be taken with caution, but Dallas moves to 2-0 in exhibition play while Arizona drops to 1-2. For the Cowboys, the bigger takeaway is the quarterback depth chart: Milton’s performance will fuel debate about his role heading into the season.

    FAQ

    What was the final score of Cowboys vs Cardinals?

    The Dallas Cowboys beat the Arizona Cardinals 34-13 in NFL preseason Week 2.

    Who scored for the Cowboys?

    Joe Milton III threw a 53-yard touchdown pass and Phil Mafah added a 15-yard rushing touchdown, as Dallas scored in every quarter.

    What are the teams’ preseason records?

    Dallas improved to 2-0 in the preseason, while Arizona fell to 1-2.

    When do the Cowboys play next?

    Dallas has one more preseason tune-up before the regular season kicks off in September.

  • Merck-Moderna mRNA melanoma vaccine hits Phase 3 RFS and DMFS

    Merck-Moderna mRNA melanoma vaccine hits Phase 3 RFS and DMFS

    Merck-Moderna mRNA melanoma vaccine hits Phase 3 RFS and DMFS

    By Patrick Lancier

    TL;DR — On Wednesday 19 August 2026 Merck and Moderna said an experimental individualized mRNA vaccine plus KEYTRUDA met late-stage endpoints in resected advanced melanoma. Merck, at 6:45 a.m. EDT, named the trial: Phase 3 INTerpath-001, intismeran autogene (V940 / mRNA-4157), 1,137 patients randomised 2:1, completely resected stage IIB-IV disease, NCT05933577. Primary recurrence-free survival and key secondary distant metastasis-free survival were met at a pre-specified interim analysis. France 24 / AFP, at 14:11, quotes the joint statement as the first positive Phase 3 readout for an mRNA-based cancer therapy, and stresses that no numerical data were published. The study continues for overall survival. This is not an approval. It is not a cure. It is not a Phase 3 hazard ratio.

    What INTerpath-001 met — and what Wednesday did not quantify

    Merck’s wording is specific. The combination met the primary RFS endpoint and the key secondary DMFS endpoint. It is described as the first positive Phase 3 for an individualized neoantigen therapy and for an mRNA-based cancer therapy, and as the first Phase 3 with a clinically meaningful improvement over KEYTRUDA alone in adjuvant resected melanoma. Safety was called consistent, with no new signals. AFP, relaying the same announcement, says the KEYTRUDA combination improved recurrence-free survival statistically significantly versus KEYTRUDA alone, in more than 1,100 people, without a table. Those two registers — clinically meaningful, statistically significant — are not a hazard ratio. No Phase 3 HR, median, or death count from the trial appears in these sources. None is invented here.

    The 49% reduction in recurrence or death (HR=0.51; 95% CI 0.294-0.887) and the 59% reduction in distant metastasis or death (HR=0.411; 95% CI 0.200-0.843) sit in the same Merck release under a different heading: KEYNOTE-942, Phase 2b, five-year data at ASCO 2026. They are not INTerpath-001. Treating 49 and 59 as Wednesday’s Phase 3 result would mis-assign the year. Epidemiology in the same file is also not a trial event: labs, via AFP, put melanoma at more than 330,000 new cases worldwide in 2022; Merck estimates about 112,000 US cases and over 8,500 deaths in 2026; CNBC notes melanoma is about 1% of skin cancers but the large majority of skin-cancer deaths.

    Regulators, overall survival, and what is not an approval

    AFP says the companies will present the data at a medical congress and start steps with authorities toward approval. That is an intention, not a licence. CNBC writes that it is unclear when they plan to submit US applications. Dean Li, Merck Research Labs, told Squawk Box they will likely start talking to regulators about treatment and safety in the next few months. Bancel called it a big moment for medicine, a big moment for patients. A big moment is a quote. It is not a marketing authorization. Merck and CNBC both say the study continues for overall survival. An OS curve is not what Wednesday published.

    The patient population in these pieces is adjuvant: surgery already done, stage IIB-IV, vaccine plus KEYTRUDA versus KEYTRUDA alone. It is not described here as a substitute for KEYTRUDA, and not as a first-line unresectable metastatic trial. Wednesday’s public file is a dual endpoint met at interim, a safety line with no new signals, and an OS follow-up that is still running.

    Two market prints — premarket Reuters and the CNBC session — not one close

    Reuters, via Boursier at 15:06 on 19 August 2026, is labelled here as premarket only: Moderna +60% to $103.60, Merck +7.5% before the open. CNBC’s session figures are different objects: Moderna soared about 177%, Merck climbed more than 12% Wednesday. CNBC also places market caps entering Wednesday at around $333 billion for Merck and near $25 billion for Moderna. Those caps are entry figures, not a close. No source in this file publishes a single closing price that reconciles 60% with 177%. This article does not mint one. The $103.60 print belongs to Reuters premarket. It does not belong, in these pieces, to CNBC’s about-177% session move.

    The equity reaction is a reaction to a qualitative Phase 3 hit — RFS and DMFS met, no public Phase 3 HR, OS still open. Mixing the two prints, or pasting KEYNOTE-942’s 49/59 onto INTerpath-001, or calling Wednesday an approval, would be a sourcing error. The English record of 19 August 2026 stops before those steps. So does this article.

    FAQ

    Did the companies publish Phase 3 numbers on Wednesday?

    No. France 24 / AFP says the joint statement reported a statistically significant RFS improvement versus KEYTRUDA alone without numerical data. This article does not invent a Phase 3 hazard ratio.

    What did INTerpath-001 meet?

    Merck: primary recurrence-free survival (RFS) and key secondary distant metastasis-free survival (DMFS) at a pre-specified interim analysis. 1,137 patients randomised 2:1, NCT05933577, completely resected stage IIB-IV melanoma.

    Are the 49% and 59% figures from Phase 3?

    No. Merck attaches them to KEYNOTE-942, a Phase 2b five-year update at ASCO 2026: 49% reduction in recurrence or death (HR=0.51; 95% CI 0.294-0.887) and 59% in distant metastasis or death (HR=0.411; 95% CI 0.200-0.843).

    Is this an approval, or a cure?

    No. AFP: the companies will present data at a medical congress and start steps with authorities toward approval. CNBC: unclear when they plan to submit US applications. Dean Li told Squawk Box they will likely start talking to regulators about treatment and safety in the next few months. The study continues for OS.

    How should the two stock prints be read?

    Separately. Reuters via Boursier, 19 August 2026 15:06, is premarket only: Moderna +60% to $103.60, Merck +7.5% before the open. CNBC session: Moderna soared about 177%, Merck climbed more than 12% Wednesday. Caps entering Wednesday: Merck around $333 billion, Moderna near $25 billion. No single close reconciling 60% and 177% is published here.

    Sources


    By Patrick Lancier


  • US debt tops $40 trillion for the first time, Treasury says

    US debt tops $40 trillion for the first time, Treasury says

    US debt tops $40 trillion for the first time, Treasury says

    “By Patrick Lancier”

    TL;DR — France 24, citing AFP, reports that US Treasury debt reached $40.047 trillion after Tuesday’s bill sale. The figures were published Wednesday, 19 August, by the Treasury. It is the first time the $40 trillion mark has been crossed. The Congressional Budget Office had expected $39.4 trillion by year-end. Tuesday’s 30-year Treasury yield hit its highest level since 2007. Wednesday, Treasury said it would enlarge long-term bond buybacks from September; France 24 writes that investors were reassured and yields eased. No yield print is in the dispatch. This piece does not invent one. This is not a default.

    What is $40.047 trillion, and what is $39.4 trillion?

    The first number is an outstanding stock after Tuesday’s issuance, published Wednesday. The second is a CBO year-end forecast. France 24 says the rise has been faster than expected. It does not subtract 647 billion as a “miss.” Drivers named: borrowing tied to health care and Social Security, and interest costs. The same article links higher borrowing costs to inflation, Middle East conflict and energy prices. Tuesday: 30-year at a 2007 high. Wednesday: larger long-term buybacks from September. France 24: investors reassured, rates eased. No buyback size is published.

    Riedl and Quakenbush: quotes, not a rating action

    Jessica Riedl, Brookings Institution, to France 24: “It is well known that the federal government has a deficit pace that is not sustainable.” She puts deficits around 6% to 7% of GDP, versus 3% to 4% that used to worry markets. “That has made markets more nervous.” Caleb Quakenbush, Bipartisan Policy Center, to AFP: the path has not been addressed by Congress or administrations in a “significant or lasting” way, which could pose serious challenges in a new crisis. France 24: debt has more than doubled since 2008 and stands near 125% of GDP. Analysts note there is no debt-to-GDP level that automatically triggers a crisis, and that debt held by the public — excluding intra-governmental holdings — is the most watched gauge. Riedl: psychological thresholds alert markets.

    Donald Trump promised in both terms to cut spending and shrink the annual deficit. Scott Bessent’s goal, France 24 says, was a deficit of 3% of GDP. The deficit widened in recent months, including because of tariff refunds to firms after the Supreme Court struck the tariffs down in February. Tax cuts and military spending, especially tied to the Iran conflict, “also swallowed many billions of dollars.” France 24 gives no Iran total. This article adds none.

    FAQ

    What is the exact Treasury figure?

    $40.047 trillion after Tuesday’s sale, published Wednesday 19 August, according to France 24 / AFP.

    Did CBO expect $40 trillion this year?

    No. It expected $39.4 trillion by year-end.

    Is a 30-year yield printed?

    No. Only “highest since 2007,” Tuesday.

    Is this a default?

    No. A stock threshold, high yields, and larger buybacks from September.

    Is 125% of GDP debt held by the public?

    France 24 gives about 125% for “the country’s debt,” and separately says debt held by the public is the most watched indicator. Do not merge them.

    Sources


    “By Patrick Lancier”


  • AUSTRAC’s Operation Claw flags coordinated liar loans across 10 major banks

    AUSTRAC’s Operation Claw flags coordinated liar loans across 10 major banks

    AUSTRAC’s Operation Claw flags coordinated liar loans across 10 major banks

    By Patrick Lancier

    TL;DR — AUSTRAC, on 19 August 2026, uncovered coordinated mortgage fraud that ABC News (Daniel Ziffer) puts at “hundreds of millions of dollars” across 10 major banks. The operation is called Claw. The properties are mostly in Sydney. CEO Brendan Thomas calls it a “wake-up call” for every lender. No bank is named. There is no verdict and no finding of widespread money laundering. AML Intelligence writes “potentially hundreds of millions”.

    How did AUSTRAC describe the liar-loan pattern?

    The mechanism, as AUSTRAC describes it, is not a new product. Incomes are inflated. Employment is misstated. A business activity is fabricated, or made impossible to verify. Those three levers are enough to push through a file that, read against responsible-lending rules, should not have passed. ABC files them under “liar loans”: loans whose paperwork lies, in whole or in part, about the borrower’s capacity to repay.

    Sometimes the lie does not stop at the income page. Offshore funds, or money paid by a third party, are used to complete the purchase and to meet the repayments. The agency says false income flows and complex structures can wash money through Australian property. That is not a finding against a named borrower. It is the pattern the financial-intelligence agency says it has seen, repeatedly, at lenders that together cover the vast majority of the country’s mortgage market.

    AUSTRAC: why are the properties mostly in Sydney?

    ABC locates most of the purchases in Sydney. That is not local colour. It is the country’s most expensive market, the one where a file that looks a little too good opens the door to a large ticket. Operation Claw, the same article says, has exposed coordinated mortgage fraud and “systemic weaknesses” in lending. The purchases do not meet the rules meant to guarantee a responsible loan and to limit cash-sale entry.

    Thomas puts it without ornament: “The same warning signs were found across banks that together cover the vast majority of Australia’s mortgage market.” The project did not target a single boutique. It looked at lenders large enough that the same flag, seen ten times, stops being an anecdote. AML Intelligence adds that the activity “was not confined to one lender or borrower group”. Not one bank. Not one borrower profile.

    What exactly is Brendan Thomas asking lenders to do?

    “The scale of this activity should be a wake-up call for every lender.” The sentence is in ABC, attributed to AUSTRAC’s chief executive. It names no one. It addresses the whole market. Thomas adds that the most effective way to stop mortgage fraud is before the loan is approved. Once the credit is in place and the funds are gone, recovery becomes “significantly harder”.

    He has already referred files. The partners named are the banks themselves, the ATO, NSW Police, the NSW Crime Commission, ACIC, APRA and ASIC. That is not a conviction. It is a referral queue. AUSTRAC has named none of the 10 banks. A reader looking for a league table will not find one here. The instruction, as Ziffer reports it, is three verbs: look at the signs, strengthen controls, report suspicious activity. The project “did not identify evidence of widespread money laundering”. Thomas adds that the weaknesses exposed could be exploited by criminals. Both sentences stay on the record.

    Have banks already cut ties — and what does the ABA want?

    AML Intelligence writes that some banks have already “ended” relationships, and that AUSTRAC expects further action. That is not a public disqualification. It is a lender-side exit after potentially fraudulent loans were identified. It is a risk signal, not a criminal finding. The same piece says the same brokers, accountants and law firms appear across multiple applications, and that names of individuals and entities potentially involved in false documents have already gone to the ATO and the Tax Practitioners Board.

    Simon Birmingham, for the Australian Banking Association, welcomes AUSTRAC’s action. The industry says it already shares through Fintel Alliance — AUSTRAC’s public-private partnership page, not a Claw press release on austrac.gov.au. Banks want secure access to ATO income data, “a single, trusted source of truth”. ABC does not say Canberra has granted that access. On 19 August it is still an industry ask, attached to a regulatory wake-up.

    How should earlier UBS and RAMS figures be read — separately from Claw?

    The subject did not begin on 19 August. ABC says so, and the figures must be kept apart. In 2021 UBS surveyed about 900 people: 41% of files were not entirely accurate. The most common gaps were living costs (34%), commitments (28%) and income (22%). Broker-originated files were inaccurate at 44%, against 29% written direct to the bank. That is not a Claw number. It is five-year-old survey context.

    Other context, clearly separated: ASIC sued RAMS, then a Westpac subsidiary, over systemic loan-arrangement failures, including fake payslips. In October the Federal Court imposed a A$20 million penalty after an admission of “widespread compliance failures”. This month the RAMS book was sold to Pepper Money for A$15.4 billion. None of that is an Operation Claw result. ABC offers it to show the market already knows the doctored file. Claw itself is a 2026 coordinated-fraud alert, with no bank named and no verdict.

    FAQ

    What is Operation Claw, according to ABC?

    An AUSTRAC operation that uncovered coordinated mortgage fraud, “worth hundreds of millions of dollars”, at 10 major banks, with “systemic weaknesses” in lending. The properties are mostly in Sydney. No bank is named.

    Has AUSTRAC named the 10 banks?

    No. Neither ABC nor AML Intelligence publishes their names. Thomas says only that the same signs were found at banks that together cover the vast majority of Australia’s mortgage market.

    Is there evidence of widespread money laundering?

    No. Thomas says the project “did not identify evidence of widespread money laundering”. He adds that the weaknesses exposed could be exploited by criminals. That is not a verdict.

    What is a “liar loan” in this file?

    A loan whose paperwork, according to AUSTRAC, rests on inflated income, misstated employment, or a fabricated or unverifiable business. Sometimes offshore or third-party funds are used for the balance and the repayments.

    Do the UBS and RAMS figures belong to Claw?

    No. The 2021 UBS survey (about 900 people, 41% of files not entirely accurate) and the A$20 million RAMS penalty are ABC context, clearly separated. They are not Operation Claw results.

    Sources


    By Patrick Lancier